Lantheus Holdings, Inc. (NASDAQ:LNTH) Short Interest Down 13.3% in February

Lantheus Holdings, Inc. (NASDAQ:LNTH) was the recipient of a large decline in short interest in February. As of February 28th, there was short interest totalling 6,340,000 shares, a decline of 13.3% from the February 13th total of 7,310,000 shares. Based on an average daily trading volume, of 902,000 shares, the days-to-cover ratio is presently 7.0 days. Currently, 9.5% of the company’s stock are sold short.

Insiders Place Their Bets

In other news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company’s stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,109 shares of company stock worth $5,105,606 in the last quarter. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LNTH. Janus Henderson Group PLC increased its stake in Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock valued at $554,583,000 after buying an additional 2,610,118 shares during the period. Farallon Capital Management LLC increased its stake in Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock valued at $475,590,000 after buying an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock valued at $135,025,000 after buying an additional 435,445 shares during the period. Raymond James Financial Inc. acquired a new position in Lantheus in the 4th quarter valued at approximately $36,183,000. Finally, Groupama Asset Managment acquired a new position in Lantheus in the 3rd quarter valued at approximately $439,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Up 0.2 %

NASDAQ LNTH traded up $0.17 on Wednesday, hitting $102.39. The stock had a trading volume of 91,070 shares, compared to its average volume of 935,511. Lantheus has a one year low of $56.52 and a one year high of $126.89. The stock has a market cap of $7.01 billion, a price-to-earnings ratio of 17.03 and a beta of 0.38. The company’s 50-day moving average is $92.35 and its two-hundred day moving average is $96.64.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. On average, sell-side analysts anticipate that Lantheus will post 6.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LNTH. JMP Securities reissued a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. Finally, StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $132.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.